R. Watanabe, Daisuke Tsuji, H. Tanaka, MS. Uno, Y. Ohnishi, S. Kitaguchi, T. Matsugu, R. Nakae, H. Teramoto, Kei Yamamoto, Yasuo Shinohara, T. Hirokawa, N. Okino, M. Ito and K. Itoh : Lysoglycosphingolipids have the ability to induce cell death through direct PI3K inhibition., Journal of Neurochemistry, Vol.167, No.6, 753-765, 2023.
(Summary)
Sphingolipidoses are inherited metabolic disorders associated with glycosphingolipids accumulation, neurodegeneration, and neuroinflammation leading to severe neurological symptoms. Lysoglycosphingolipids (lysoGSLs), also known to accumulate in the tissues of sphingolipidosis patients, exhibit cytotoxicity. LysoGSLs are the possible pathogenic cause, but the mechanisms are still unknown in detail. Here, we first show that lysoGSLs are potential inhibitors of phosphoinositide 3-kinase (PI3K) to reduce cell survival signaling. We found that phosphorylated Akt was commonly reduced in fibroblasts from patients with sphingolipidoses, including GM1/GM2 gangliosidoses and Gaucher's disease, suggesting the contribution of lysoGSLs to the pathogenesis. LysoGSLs caused cell death and decreased the level of phosphorylated Akt as in the patient fibroblasts. Extracellularly administered lysoGM1 permeated the cell membrane to diffusely distribute in the cytoplasm. LysoGM1 and lysoGM2 also inhibited the production of phosphatidylinositol-(3,4,5)-triphosphate and the translocation of Akt from the cytoplasm to the plasma membrane. We also predicted that lysoGSLs could directly bind to the catalytic domain of PI3K by in silico docking study, suggesting that lysoGSLs could inhibit PI3K by directly interacting with PI3K in the cytoplasm. Furthermore, we revealed that the increment of lysoGSLs amounts in the brain of sphingolipidosis model mice correlated with the neurodegenerative progression. Our findings suggest that the down-regulation of PI3K/Akt signaling by direct interaction of lysoGSLs with PI3K in the brains is a neurodegenerative mechanism in sphingolipidoses. Moreover, we could propose the intracellular PI3K activation or inhibition of lysoGSLs biosynthesis as novel therapeutic approaches for sphingolipidoses because lysoGSLs should be cell death mediators by directly inhibiting PI3K, especially in neurons.
H. Hakoi, Y. Miki, S. Nomura, K. Nakajima, C. Terashima-Murase, T. Takeichi, S. Sano, M. Akiyama, SI. Sakasegawa, M. Murakami and Kei Yamamoto : Lysophospholipase D from Thermocrispum limits psoriatic inflammation by hydrolyzing epidermal lysoplasmalogen produced by group IIF secreted phospholipase A2, Biochimie, Vol.215, 75-87, 2023.
(Summary)
Epidermal lipids play important roles in skin homeostasis and diseases. Psoriasis is an inflammatory disease characterized by keratinocyte hyperproliferation and Th17 immune responses. We previously reported that ethanolamine-type lysoplasmalogen (P-LPE), preferentially produced by group IIF secreted PLA (sPLA-IIF/PLA2G2F) that is expressed in the suprabasal epidermis, promotes epidermal hyperplasia in psoriatic inflammation. Herein, we show that forcible degradation of epidermal P-LPE by topical application of recombinant lysophospholipase D (LyPls-PLD) from Thermocrispum, a lysoplasmalogen-specific hydrolase, attenuated epidermal hyperplasia and inflammation in imiquimod-induced and K5.Stat3C-transgenic mouse psoriasis models. In humans, P-LPE levels were elevated in the tape-stripped stratum corneum of patients with psoriasis. Moreover, in primary cultured human epidermal keratinocytes, aberrant cell proliferation and activation by psoriatic cytokines were sPLA-IIF/P-LPE-dependent and were suppressed by the addition of LyPls-PLD with a decrease in P-LPE. These findings confirm that the sPLA-IIF/P-LPE axis in the epidermis indeed regulates psoriasis, that P-LPE is a lipid biomarker that predicts the severity of psoriasis, and that pharmacological removal of this bioactive lipid is useful to prevent the disease. Thus, our study may lead to the development of drug discovery and diagnostic techniques based on this pathway.
Kei Yamamoto, Haruka Hakoi, Saki Nomura and Makoto Murakami : The roles of sPLA2s in skin homeostasis and disease., Biomolecules, Vol.13, No.4, 668, 2023.
(Summary)
Among the phospholipase A (PLA) family, the secreted PLA (sPLA) family in mammals contains 11 members that exhibit unique tissue or cellular distributions and enzymatic properties. Current studies using knockout and/or transgenic mice for a nearly full set of sPLAs, in combination with comprehensive lipidomics, have revealed the diverse pathophysiological roles of sPLAs in various biological events. Individual sPLAs exert specific functions within tissue microenvironments, likely through the hydrolysis of extracellular phospholipids. Lipids are an essential biological component for skin homeostasis, and disturbance of lipid metabolism by deletion or overexpression of lipid-metabolizing enzymes or lipid-sensing receptors often leads to skin abnormalities that are easily visible on the outside. Over the past decades, our studies using knockout and transgenic mice for various sPLAs have uncovered several new aspects of these enzymes as modulators of skin homeostasis and disease. This article summarizes the roles of several sPLAs in skin pathophysiology, providing additional insight into the research fields of sPLAs, lipids, and skin biology.
I. Tsukayama, Y. Kawakami, A. Tanenobu, K. Toda, S. Maruoka, Y. Nagasaki, Y. Mori, R. Sawazumi, K. Okamoto, K. Kanzaki, H. Ito, Y. Takahashi, Y. Miki, Kei Yamamoto, M. Murakami and T. Suzuki-Yamamoto : Malabaricone C inhibits arachidonate 5-lipoxygenase activity and improves psoriasis-like skin inflammation in mice., Free Radical Biology and Medicine, Vol.193, 1-8, 2022.
(Summary)
As pro-inflammatory lipid mediators, leukotrienes have pathophysiological activities in several inflammatory diseases, including psoriasis. In the biosynthesis of leukotrienes from arachidonic acid, 5-lipoxygenase catalyzes the first two steps. In the present study, we showed that nutmeg (Myristica fragrans) strongly inhibited the catalytic activity of 5-lipoxygenase. To characterize the bioactive component(s) of nutmeg, we performed 5-lipoxygenase inhibitory activity-guided fractionation of aqueous ethanol extract of nutmeg, resulting in the isolation of malabaricone C having antioxidant activity. Malabaricone C exhibited potent competitive inhibition of 5-lipoxygenase with an IC value of 0.2 μM. In mice with imiquimod-induced psoriasis-like skin lesions, topical application of 2 mM malabaricone C significantly ameliorated hyperplasia and inflammatory cell infiltration, and suppressed the expression of the psoriasis-associated genes S100a9, Krt1, Il17a, and Il22. Lipid metabolome analysis of these psoriasis-like skin lesions showed that malabaricone C markedly decreased the level of leukotriene B but did not significantly increase the other pro-inflammatory lipid mediators. These findings suggest that malabaricone C decreases LTB by the 5-lipoxygenase inhibition and ameliorates the symptoms of psoriasis-like skin inflammation.
Y. Nagasaki, E. Kawai, S. Maruoka, M. Osumi, I. Tsukayama, Y. Kawakami, Y. Takahashi, Y. Okazaki, Y. Miki, Y. Taketomi, Kei Yamamoto, M. Murakami and T. Suzuki-Yamamoto : Lipid profiling reveals the presence of unique lipid mediators in human milk from healthy and mastitic subjects., Biochemical and Biophysical Research Communications, Vol.630, 84-91, 2022.
(Summary)
Milk lipids are an important energy source for infants, but the composition of milk lipids has not yet been clarified in detail. In this study, we analyzed free fatty acids and their metabolites in milk from humans and cows. In comparison to cow milk, human milk showed a higher content of free fatty acids including polyunsaturated fatty acids, especially ω-3 fatty acids and their metabolites. Polyunsaturated fatty acids were enriched at an early period of lactation, while saturated fatty acids did not change significantly over the period. Moreover, human milk contained high levels of ω-3 fatty acid metabolites, particularly 18-hydroxyeicosapentaenoic acid, an eicosapentaenoic acid-derived metabolite with anti-inflammatory activity. In comparison with human normal milk, thromboxane B and protectin D1 levels were significantly elevated in milk from individuals with mastitis, suggesting that these lipid mediators could be potential biomarkers of obstructive mastitis. Overall, the unique lipid profile of human milk supports the efficacy of breast-feeding for supply of more nutritional and bioactive lipids in comparison to artificial or cow milk to infants, in whom digestive and absorptive functions are still immature.
K. Kudo, Y. Miki, J. Carreras, S. Nakayama, Y. Nakamoto, M. Ito, E. Nagashima, Kei Yamamoto, H. Higuchi, SY. Morita, A. Inoue, J. Aoki, K. Ando, N. Nakamura, M. Murakami and A. Kotani : Secreted phospholipase A2 modifiers extracellular vesicles and accelerates B cell lymphoma., Cell Metabolism, Vol.34, No.4, 615-633, 2022.
(Summary)
Extracellular vesicles (EVs) including exosomes act as intercellular communicators by transferring protein and microRNA cargoes, yet the role of EV lipids remains unclear. Here, we show that the pro-tumorigenic action of lymphoma-derived EVs is augmented via secreted phospholipase A (sPLA)-driven lipid metabolism. Hydrolysis of EV phospholipids by group X sPLA, which was induced in macrophages of Epstein-Barr virus (EBV) lymphoma, increased the production of fatty acids, lysophospholipids, and their metabolites. sPLA-treated EVs were smaller and self-aggregated, showed better uptake, and increased cytokine expression and lipid mediator signaling in tumor-associated macrophages. Pharmacological inhibition of endogenous sPLA suppressed lymphoma growth in EBV-infected humanized mice, while treatment with sPLA-modified EVs reversed this phenotype. Furthermore, sPLA expression in human large B cell lymphomas inversely correlated with patient survival. Overall, the sPLA-mediated EV modification promotes tumor development, highlighting a non-canonical mechanistic action of EVs as an extracellular hydrolytic platform of sPLA.
Y. Miki, Y. Taketomi, Y. Kidoguchi, Kei Yamamoto, K. Muramatsu, Y. Nishito, J. Park, K. Hosomi, K. Mizoguchi, J. Kunisawa, T Soga, E. Boilard, S.G.B. Gowda, K. Ikeda, M. Arita and M. Murakami : Group IIA secreted phospholipase A2 controls skin carcinogenesis and psoriasis by shaping the gut microbiota., JCI Insight, Vol.7, No.2, e152611, 2022.
(Summary)
Besides promoting inflammation by mobilizing lipid mediators, group IIA secreted phospholipase A2 (sPLA2-IIA) prevents bacterial infection by degrading bacterial membranes. Here, we show that, despite the restricted intestinal expression of sPLA2-IIA in BALB/c mice, its genetic deletion leads to amelioration of cancer and exacerbation of psoriasis in distal skin. Intestinal expression of sPLA2-IIA is reduced after treatment with antibiotics or under germ-free conditions, suggesting its upregulation by gut microbiota. Metagenome, transcriptome, and metabolome analyses have revealed that sPLA2-IIA deficiency alters the gut microbiota, accompanied by notable changes in the intestinal expression of genes related to immunity and metabolism, as well as in the levels of various blood metabolites and fecal bacterial lipids, suggesting that sPLA2-IIA contributes to shaping of the gut microbiota. The skin phenotypes in Pla2g2a-/- mice are lost (a) when they are cohoused with littermate WT mice, resulting in the mixing of the microbiota between the genotypes, or (b) when they are housed in a more stringent pathogen-free facility, where Pla2g2a expression in WT mice is low and the gut microbial compositions in both genotypes are nearly identical. Thus, our results highlight a potentially new aspect of sPLA2-IIA as a modulator of gut microbiota, perturbation of which affects distal skin responses.
Kei Yamamoto : Elucidation of mechanism of skin homeostasis and disease regulation by plasmalogen-type lysophospholipid pathway., Annual Report of Cosmetology, Vol.28, 162-166, 2020.
H. Sato, Y. Taketomi, Y. Miki, R. Murase, Kei Yamamoto and M. Murakami : Secreted phospholipase PLA2G2D contributes to metabolic health by mobilizing omega-3 polyunsaturated fatty acids in white adipose tissue., Cell Reports, Vol.31, No.5, 107579, 2020.
(Summary)
Polyunsaturated fatty acids (PUFAs) confer health benefits by preventing inflammation and obesity and by increasing thermogenesis in brown and beige adipocytes. As well as being supplied exogenously as nutrients, PUFAs are largely stored in membrane glycerophospholipids and released by phospholipase As (PLAs). However, the molecular identity of the PLA subtype(s) that supplies endogenous PUFAs for metabolic homeostasis remains unclear. Here we show that PLA2G2D, a secreted PLA isoform, is constitutively expressed in M2-type macrophages in white adipose tissue (WAT) and shows a reciprocal correlation with obesity. Studies using global and macrophage-specific Pla2g2d-deficient mice reveal that PLA2G2D increases energy expenditure and thermogenesis by facilitating adipocyte browning, thereby ameliorating diet-induced obesity, insulin resistance, and WAT inflammation. Mechanistically, PLA2G2D constitutively supplies a pool of PUFAs, ω3 in particular, in WAT. Thus, our present findings underscore the contribution of the macrophage-driven PLA2G2D-ω3 PUFA axis to metabolic health.
K. Toda, I. Tsukayama, Y. Nagasaki, Y. Konoike, A. Tanenobu, N. Ganeko, H. Ito, Y. Kawakami, Y. Takahashi, Y. Miki, Kei Yamamoto, M. Murakami and T. Suzuki-Yamamoto : Red-kerneled rice proanthocyanidin inhibits arachidonate 5-lipoxygenase and decreases psoriasis-like skin inflammation., Archives of Biochemistry and Biophysics, Vol.689, 108307, 2020.
(Summary)
5-lipoxygenase is a key enzyme in the synthesis of leukotrienes from arachidonic acid. The produced leukotrienes are involved in inflammatory diseases including psoriasis, asthma, and atherosclerosis. A suitable 5-lipoxygenase inhibitor might be useful for preventing and improving the symptoms of leukotriene-related inflammatory diseases. Here, we investigate the mechanism underlying the anti-inflammatory effect of a proanthocyanidin found in red-kerneled rice. Red-kerneled rice proanthocyanidin exhibited potent mixed noncompetitive inhibition of human and rat 5-lipoxygenases, with an IC values of 15.1 μM against human enzyme, and 7.0 μM against rat enzyme, respectively. This compound decreased leukotriene B production in rat basophilic leukemia-2H3 cells. In imiquimod-induced psoriasis-like mouse skin, topical application of the proanthocyanidin suppressed hyperplasia, decreased inflammatory cell infiltration, and down-regulated expression of the psoriasis-associated genes Il17a, Il22, S100a9, and Krt1. Lipid metabolome analysis by electrospray ionization mass spectrometry showed that red-kerneled rice proanthocyanidin treatment of psoriasis-like mouse skin dose-dependently decreased the production of leukotriene B but no other arachidonate metabolites. Red-kerneled rice proanthocyanidin inhibits 5-lipoxygenase, resulting in a decrease in leukotriene B production and psoriasis-like mouse skin inflammation. These results suggest that this proanthocyanidin may be therapeutically effective for treating leukotriene-related diseases.
Akio Mori, Taku Hatano, Tsuyoshi Inoshita, Kahori Shiba-Fukushima, Takahiro Koinuma, Hongrui Meng, Shin-ichiro Kubo, Spencer Spratt, Changxu Cui, Chikara Yamashita, Yoshimi Miki, Kei Yamamoto, Tetsuya Hirabayashi, Makoto Murakami, Yoshikazu Yakahashi, Hideo Shindou, Takashi Nonaka, Masato Hasegawa, Ayami Okuzumi, Yuzuru Imai and Nobutaka Hattori : Parkinsons disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling, Proceedings of the National Academy of Sciences of the United States of America, Vol.116, No.41, 20689-20699, 2019.
(Summary)
Mutations in the gene are responsible for -linked Parkinson's disease (PD) with α-synucleinopathy. However, it is unclear how mutations lead to α-synuclein (α-Syn) aggregation and dopaminergic (DA) neurodegeneration. Here, we report that -deficient exhibits defects in neurotransmission during early developmental stages and progressive cell loss throughout the brain, including degeneration of the DA neurons. Lipid analysis of brain tissues reveals that the acyl-chain length of phospholipids is shortened by loss, which causes endoplasmic reticulum (ER) stress through membrane lipid disequilibrium. The introduction of wild-type human iPLA2-VIA or the mitochondria-ER contact site-resident protein C19orf12 in -deficient flies rescues the phenotypes associated with altered lipid composition, ER stress, and DA neurodegeneration, whereas the introduction of a disease-associated missense mutant, A80T, fails to suppress these phenotypes. The acceleration of α-Syn aggregation by loss is suppressed by the administration of linoleic acid, correcting the brain lipid composition. Our findings suggest that membrane remodeling by iPLA2-VIA is required for the survival of DA neurons and α-Syn stability.
S. Sakasegawa, S. Taira, Kei Yamamoto and D. Sugimori : Enzymatic Synthesis of 1-alkyl-2-hydroxy-sn-glycero-2,3-cyclic-phosphate Using Lysoplasmalogen-specific Phospholipase D., European Journal of Lipid Science and Technology : EJLST, 1900227, 2019.
Makoto Murakami, Kei Yamamoto and Yoshitaka Taketomi : Phospholipase A2 in skin biology: new insights from gene-manipulated mice and lipidomics., Inflammation and Regeneration, Vol.38, 31, 2018.
(Summary)
The skin represents one of the tissues that are most profoundly influenced by alterations in the quality of lipids (lipoquality). Lipids not only constitute cellular membranes, but also serve as bioactive lipid mediators and essential components of the skin barrier. Phospholipase A (PLA) enzymes supply fatty acids and lysophospholipids from membrane phospholipids, thereby variably affecting cutaneous homeostasis. Accordingly, perturbation of particular PLA-driven lipid pathways can be linked to various forms of skin disease. In this review article, we highlight the roles of several PLA subtypes in cutaneous pathophysiology, as revealed by transgenic/knockout studies in combination with comprehensive lipidomics. We focus mainly on secreted PLA group IIF (sPLA-IIF), which is associated with epidermal hyperplasia through mobilization of a unique lipid metabolite. We also address the distinct roles of sPLA-IIE in hair follicles and sPLA-IID in lymphoid immune cells that secondarily affect cutaneous inflammation, and provide some insights into species differences in sPLAs. Additionally, we briefly overview the patatin-like phospholipase PNPLA1, which belongs to the Ca-independent PLA (iPLA) family, as a key regulator of skin barrier function through catalysis of a unique non-PLA reaction. These knowledges on lipid metabolism driven by various PLA subtypes will open novel opportunities for translated studies toward diagnosis and therapy of human skin diseases.
I. Tsukayama, K. Toda, Y. Takeda, T. Mega, M. Tanaka, Y. Kawakami, Y. Takahashi, M. Kimoto, Kei Yamamoto, Y. Miki, M. Murakami and T. Suzuki-Yamamoto : Preventive effect of Dioscora japonica on squamous cell carcinoma of mouse skin involving down-regulation of prostaglandin E2 synthetic pathway., Journal of Clinical Biochemistry and Nutrition, Vol.62, No.2, 139-147, 2018.
(Summary)
Hyperproduced prostaglandin E by cyclooxygenase-2 and microsomal prostaglandin E synthase-1 evokes several pathophysiological responses such as inflammation and carcinogenesis. Our recent study demonstrated that extract suppressed the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 and induced apoptosis in lung carcinoma A549 cells. In the present study, we investigated the effects of on squamous cell carcinoma of mouse skin. feeding and extract topical application suppressed the expression of cyclooxygenase-2, microsomal prostaglandin E synthase-1, interleukin-1β and interleukin-6 and inhibited tumor formation, hyperplasia and inflammatory cell infiltration. Immunohistochemical analyses showed the immunoreactivities of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in tumor keratinocytes and stronger immunoreactivities of cyclooxygenase-2 and hematopoietic prostaglandin D synthase in epidermal dendritic cells (Langerhans cells). Treatment with decreased the immunoreactivity of cyclooxygenase-2 and microsomal prostaglandin E synthase-1. These results indicate that may have inhibitory effects on inflammation and carcinogenesis via suppression of the prostaglandin E synthetic pathway.
Remi Murase, Yoshitaka Taketomi, Yoshimi Miki, Yasumasa Nishito, Moe Saito, Kiyoko Fukami, Kei Yamamoto and Makoto Murakami : Group III phospholipase A2 promotes colitis and colorectal cancer., Scientific Reports, Vol.7, 12261, 2017.
(Summary)
Lipid mediators play pivotal roles in colorectal cancer and colitis, but only a limited member of the phospholipase A (PLA) subtypes, which lie upstream of various lipid mediators, have been implicated in the positive or negative regulation of these diseases. Clinical and biochemical evidence suggests that secreted PLA group III (sPLA-III) is associated with colorectal cancer, although its precise role remains obscure. Here we have found that sPLA-III-null (Pla2g3 ) mice are highly resistant to colon carcinogenesis. Furthermore, Pla2g3 mice are less susceptible to dextran sulfate-induced colitis, implying that the amelioration of colonic inflammation by sPLA-III ablation may underlie the protective effect against colon cancer. Lipidomics analysis of the colon revealed significant reduction of pro-inflammatory/pro-tumorigenic lysophosholipids as well as unusual steady-state elevation of colon-protective fatty acids and their oxygenated metabolites in Pla2g3 mice. Overall, our results establish a role of sPLA-III in the promotion of colorectal inflammation and cancer, expand our understanding of the divergent roles of multiple PLA enzymes in the gastrointestinal tract, and point to sPLA-III as a novel druggable target for colorectal diseases.
Atsushi Irie, Kei Yamamoto, Yoshimi Miki and Makoto Murakami : Phosphatidylethanolamine dynamics are required for osteoclast fusion., Scientific Reports, Vol.7, 46715, 2017.
(Summary)
Osteoclasts, responsible for bone resorption, are multinucleated cells formed by cell-cell fusion of mononuclear pre-osteoclasts. Although osteoclast fusion is a pivotal step for osteoclastogenesis, little is known about the mechanism involved. To clarify the underlying process, we investigated dynamics of membrane phospholipids during osteoclastogenesis in vitro. We found that the cellular content of phospholipids, phosphatidylethanolamine (PE) in particular, was increased during osteoclast differentiation. Furthermore, PE was greatly increased in the outer leaflet of the plasma membrane bilayer during osteoclastogenesis, being concentrated in filopodia involved in cell-cell fusion. Immobilisation of the cell surface PE blocked osteoclast fusion, revealing the importance of PE abundance and distribution. To identify the molecules responsible for these PE dynamics, we screened a wide array of lipid-related genes by quantitative PCR and shRNA-mediated knockdown. Among them, a PE-biosynthetic enzyme, acyl-CoA:lysophosphatidylethanolamine acyltransferase 2 (LPEAT2), and two ATP-binding cassette (ABC) transporters, ABCB4 and ABCG1, were markedly increased during osteoclastogenesis, and their knockdown in pre-osteoclasts led to reduction in PE exposure on the cell surface and subsequent osteoclast fusion. These findings demonstrate that the PE dynamics play an essential role in osteoclast fusion, in which LPEAT2, ABCB4 and ABCG1 are key players for PE biosynthesis and redistribution.
Kei Yamamoto, Y. Miki, H. Sato, R. Murase, Y. Taketomi and M. Murakami : Secreted Phospholipase A2 Specificity on Natural Membrane Phospholipids, Methods in Enzymology, Vol.583, 101-117, 2017.
(Summary)
The secreted phospholipase A2 (sPLA2) family contains 10 catalytically active isoforms. Current in vitro biochemical studies have shown that individual sPLA2s have distinct substrate selectivity in terms of the polar head groups or sn-2 fatty acids of their substrate phospholipids. Importantly, transgenic or knockout mice for distinct sPLA2s display nonoverlapping phenotypes, arguing that they do act on different phospholipid substrates and mobilize unique lipid metabolites in vivo. In an effort to comprehensively understand lipid metabolism driven by individual sPLA2s under pathophysiological conditions, we took advantages of mass spectrometric lipidomics technology to monitor the spatiotemporal changes in phospholipids (substrates) and products (fatty acids, lysophospholipids, and their metabolites) in tissues or cells of sPLA2-transgenic or knockout mice. The in vivo lipidomic data were compared with the in vitro activity of recombinant sPLA2s toward phospholipid mixtures extracted from the target tissues, cells, or extracellular membrane components on which sPLA2s may intrinsically act. These approaches reveal that the overall tendency in in vitro assays using natural membranes is recapitulated in several in vivo systems, often with even more selective patterns of hydrolysis. In this chapter, we will summarize current understanding of the in vivo substrate specificity of sPLA2s toward natural membrane phospholipids.
H. Tanigawa, K. Miyata, Z. Tian, J. Aoi, T. Kadomatsu, S. Fukushima, A. Ogata, N. Takeda, J. Zhao, S. Zhu, K. Terada, M. Endo, J. Morinaga, T. Sugizaki, M. Sato, M. Morioka, I. Manabe, Y. Mashimo, A. Hata, Y. Taketomi, Kei Yamamoto, M. Murakami, K. Araki, M. Jinnin, H. Ihn and Y. Oike : Upreguration of ANGPTL6 in mouse keratinocytes enhances susceptibility to psoriasis, Scientific Reports, Vol.6, 34690, 2016.
(Summary)
Psoriasis is a chronic inflammatory skin disease marked by aberrant tissue repair. Mutant mice modeling psoriasis skin characteristics have provided useful information relevant to molecular mechanisms and could serve to evaluate therapeutic strategies. Here, we found that epidermal ANGPTL6 expression was markedly induced during tissue repair in mice. Analysis of mice overexpressing ANGPTL6 in keratinocytes (K14-Angptl6 Tg mice) revealed that epidermal ANGPTL6 activity promotes aberrant epidermal barrier function due to hyperproliferation of prematurely differentiated keratinocytes. Moreover, skin tissues of K14-Angptl6 Tg mice showed aberrantly activated skin tissue inflammation seen in psoriasis. Levels of the proteins S100A9, recently proposed as therapeutic targets for psoriasis, also increased in skin tissue of K14-Angptl6 Tg mice, but psoriasis-like inflammatory phenotypes in those mice were not rescued by S100A9 deletion. This finding suggests that decreasing S100A9 levels may not ameliorate all cases of psoriasis and that diverse mechanisms underlie the condition. Finally, we observed enhanced levels of epidermal ANGPTL6 in tissue specimens from some psoriasis patients. We conclude that the K14-Angptl6 Tg mouse is useful to investigate psoriasis pathogenesis and for preclinical testing of new therapeutics. Our study also suggests that ANGPTL6 activation in keratinocytes enhances psoriasis susceptibility.
Kei Yamamoto, Y. Miki, H. Sato, Y. Nishito, M.H. Gelb, Y. Taketomi and M. Murakami : Expression and function of group IIE phospholipase A2 in mouse skin., The Journal of Biological Chemistry, Vol.291, No.30, 15602-15613, 2016.
(Summary)
Recent studies using knock-out mice for various secreted phospholipase A2 (sPLA2) isoforms have revealed their non-redundant roles in diverse biological events. In the skin, group IIF sPLA2 (sPLA2-IIF), an "epidermal sPLA2" expressed in the suprabasal keratinocytes, plays a fundamental role in epidermal-hyperplasic diseases such as psoriasis and skin cancer. In this study, we found that group IIE sPLA2 (sPLA2-IIE) was expressed abundantly in hair follicles and to a lesser extent in basal epidermal keratinocytes in mouse skin. Mice lacking sPLA2-IIE exhibited skin abnormalities distinct from those in mice lacking sPLA2-IIF, with perturbation of hair follicle ultrastructure, modest changes in the steady-state expression of a subset of skin genes, and no changes in the features of psoriasis or contact dermatitis. Lipidomics analysis revealed that sPLA2-IIE and -IIF were coupled with distinct lipid pathways in the skin. Overall, two skin sPLA2s, hair follicular sPLA2-IIE and epidermal sPLA2-IIF, play non-redundant roles in distinct compartments of mouse skin, underscoring the functional diversity of multiple sPLA2s in the coordinated regulation of skin homeostasis and diseases.
Y. Miki, Y. Kidoguchi, M. Sato, Y. Taketomi, C. Taya, K. Muramatsu, M.H. Gelb, Kei Yamamoto and M Murakami : Dual roles of group IID phospholipase A2 in inflammation and cancer., The Journal of Biological Chemistry, Vol.291, No.30, 15588-15601, 2016.
(Summary)
Phospholipase A2 enzymes have long been implicated in the promotion of inflammation by mobilizing pro-inflammatory lipid mediators, yet recent evidence suggests that they also contribute to anti-inflammatory or pro-resolving programs. Group IID-secreted phospholipase A2 (sPLA2-IID) is abundantly expressed in dendritic cells in lymphoid tissues and resolves the Th1 immune response by controlling the steady-state levels of anti-inflammatory lipids such as docosahexaenoic acid and its metabolites. Here, we show that psoriasis and contact dermatitis were exacerbated in Pla2g2d-null mice, whereas they were ameliorated in Pla2g2d-overexpressing transgenic mice, relative to littermate wild-type mice. These phenotypes were associated with concomitant alterations in the tissue levels of ω3 polyunsaturated fatty acid (PUFA) metabolites, which had the capacity to reduce the expression of pro-inflammatory and Th1/Th17-type cytokines in dendritic cells or lymph node cells. In the context of cancer, however, Pla2g2d deficiency resulted in marked attenuation of skin carcinogenesis, likely because of the augmented anti-tumor immunity. Altogether, these results underscore a general role of sPLA2-IID as an immunosuppressive sPLA2 that allows the microenvironmental lipid balance toward an anti-inflammatory state, exerting beneficial or detrimental impact depending upon distinct pathophysiological contexts in inflammation and cancer.
M. Murakami, Kei Yamamoto, Y. Miki, R. Murase, H. Sato and Y. Taketomi : The roles of the secreted phospholipase A2 gene family in immunology, Advances in Immunology, Vol.132, 91-134, 2016.
(Summary)
Within the phospholipase A2 (PLA2) family that hydrolyzes phospholipids to yield fatty acids and lysophospholipids, secreted PLA2 (sPLA2) enzymes comprise the largest group containing 11 isoforms in mammals. Individual sPLA2s exhibit unique tissue or cellular distributions and enzymatic properties, suggesting their distinct biological roles. Although PLA2 enzymes, particularly cytosolic PLA2 (cPLA2), have long been implicated in inflammation by driving arachidonic acid metabolism, the precise biological roles of sPLA2s have remained a mystery over the last few decades. Recent studies employing mice gene-manipulated for individual sPLA2s, in combination with mass spectrometric lipidomics to identify their target substrates and products in vivo, have revealed their roles in diverse biological events, including immunity and associated disorders, through lipid mediator-dependent or -independent processes in given microenvironments. In this review, we summarize our current knowledge of the roles of sPLA2s in various immune responses and associated diseases.
R. Murase, H. Sato, Kei Yamamoto, A. Ushida, Y. Nishito, K. Ikeda, T. Kobayashi, T. Yamamoto, Y. Taketomi and M. Murakami : Group X secreted phospholipase A2 releases ω-3 polyunsaturated fatty acids, suppresses colitis and promotes sperm fertility, The Journal of Biological Chemistry, Vol.291, No.13, 6895-6911, 2016.
(Summary)
Within the secreted phospholipase A2 (sPLA2) family, group X sPLA2 (sPLA2-X) has the highest capacity to hydrolyze cellular membranes and has long been thought to promote inflammation by releasing arachidonic acid (AA), a precursor of pro-inflammatory eicosanoids. Unexpectedly, we found that transgenic mice globally overexpressing human sPLA2-X (PLA2G10-Tg) displayed striking immunosuppressive and lean phenotypes with lymphopenia and increased M2-like macrophages, accompanied by marked elevation of free ω-3 polyunsaturated fatty acids (PUFAs) and their metabolites. Studies using Pla2g10-deficient mice revealed that endogenous sPLA2-X, which is highly expressed in the colon epithelium and spermatozoa, mobilized ωPUFAs or their metabolites to protect against dextran sulfate-induced colitis and to promote fertilization, respectively. In colitis, sPLA2-X deficiency increased colorectal expression of Th17 cytokines, and ω3 PUFAs attenuated their production by lamina propria cells partly through the fatty acid receptor GPR120. In comparison, cytosolic phospholipase A2 (cPLA2α) protects from colitis by mobilizing ω-6 AA metabolites including prostaglandin E2. Thus, our results underscore a previously unrecognized role of sPLA2-X as an ω3 PUFA mobilizer in vivo, segregated mobilization of ω-3 and ω-6 PUFA metabolites by sPLA2-X and cPLA2α, respectively, in protection against colitis, and the novel role of a particular sPLA2-X-driven PUFA in fertilization.
Kei Yamamoto, Yoshimi Miki, Mariko Sato, Yoshitaka Taketomi, Yasumasa Nishito, Choji Taya, Kazuaki Muramatsu, Kazutaka Ikeda, Hiroki Nakanishi, Ryo Taguchi, Naotomo Kambe, Kenji Kabashima, Gérard Lambeau, Michael H. Gelb and Makoto Murakami : The role of group IIF secreted phospholipase A2 in epidermal homeostasis and hyperplasia., The Journal of Experimental Medicine, Vol.212, No.11, 1901-1919, 2015.
(Summary)
Epidermal lipids are important for skin homeostasis. However, the entire picture of the roles of lipids, particularly nonceramide lipid species, in epidermal biology still remains obscure. Here, we report that PLA2G2F, a functionally orphan-secreted phospholipase A2 expressed in the suprabasal epidermis, regulates skin homeostasis and hyperplasic disorders. Pla2g2f(-/-) mice had a fragile stratum corneum and were strikingly protected from psoriasis, contact dermatitis, and skin cancer. Conversely, Pla2g2f-overexpressing transgenic mice displayed psoriasis-like epidermal hyperplasia. Primary keratinocytes from Pla2g2f(-) (/-) mice showed defective differentiation and activation. PLA2G2F was induced by calcium or IL-22 in keratinocytes and preferentially hydrolyzed ethanolamine plasmalogen-bearing docosahexaenoic acid secreted from keratinocytes to give rise to unique bioactive lipids (i.e., protectin D1 and 9S-hydroxyoctadecadienoic acid) that were distinct from canonical arachidonate metabolites (prostaglandins and leukotrienes). Ethanolamine lysoplasmalogen, a PLA2G2F-derived marker product, rescued defective activation of Pla2g2f(-/-) keratinocytes both in vitro and in vivo. Our results highlight PLA2G2F as a previously unrecognized regulator of skin pathophysiology and point to this enzyme as a novel drug target for epidermal-hyperplasic diseases.
Rahul Vijay, Xiaoyang Hua, David K. Meyerholz, Yoshimi Miki, Kei Yamamoto, Michael Gelb, Makoto Murakami and Stanley Perlman : Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndromeCoV infection, The Journal of Experimental Medicine, Vol.212, No.11, 1851-1868, 2015.
(Summary)
Oxidative stress and chronic low-grade inflammation in the lungs are associated with aging and may contribute to age-related immune dysfunction. To maintain lung homeostasis, chronic inflammation is countered by enhanced expression of proresolving/antiinflammatory factors. Here, we show that age-dependent increases of one such factor in the lungs, a phospholipase A2 (PLA2) group IID (PLA2G2D) with antiinflammatory properties, contributed to worse outcomes in mice infected with severe acute respiratory syndrome-coronavirus (SARS-CoV). Strikingly, infection of mice lacking PLA2G2D expression (Pla2g2d(-/-) mice) converted a uniformly lethal infection to a nonlethal one (>80% survival), subsequent to development of enhanced respiratory DC migration to the draining lymph nodes, augmented antivirus T cell responses, and diminished lung damage. We also observed similar effects in influenza A virus-infected middle-aged Pla2g2d(-/-) mice. Furthermore, oxidative stress, probably via lipid peroxidation, was found to induce PLA2G2D expression in mice and in human monocyte-derived macrophages. Thus, our results suggest that directed inhibition of a single inducible phospholipase, PLA2G2D, in the lungs of older patients with severe respiratory infections is potentially an attractive therapeutic intervention to restore immune function.
Makoto Murakami, Hiroyasu Sato, Yoshimi Miki, Kei Yamamoto and Yoshitaka Taketomi : A new era of secreted phospholipase A2., Journal of Lipid Research, Vol.56, No.7, 1248-1261, 2015.
(Summary)
Among more than 30 members of the phospholipase A2 (PLA2) superfamily, secreted PLA2 (sPLA2) enzymes represent the largest family, being Ca(2+)-dependent low-molecular-weight enzymes with a His-Asp catalytic dyad. Individual sPLA2s exhibit unique tissue and cellular distributions and enzymatic properties, suggesting their distinct biological roles. Recent studies using transgenic and knockout mice for nearly a full set of sPLA2 subtypes, in combination with sophisticated lipidomics as well as biochemical and cell biological studies, have revealed distinct contributions of individual sPLA2s to various pathophysiological events, including production of pro- and anti-inflammatory lipid mediators, regulation of membrane remodeling, degradation of foreign phospholipids in microbes or food, or modification of extracellular noncellular lipid components. In this review, we highlight the current understanding of the in vivo functions of sPLA2s and the underlying lipid pathways as revealed by a series of studies over the last decade.
M. Murakami, Y. Taketomi, Y. Miki, H. Sato, Kei Yamamoto and G. Lambeau : Emerging roles of secreted phospholipase A2 enzymes: the 3rd edition., Biochimie, Vol.107, No.PtA, 105-113, 2014.
(Summary)
Within the phospholipase A2 (PLA2) superfamily, secreted PLA2 (sPLA2) enzymes comprise the largest family that contains 11 to 12 mammalian isoforms with a conserved His-Asp catalytic dyad. Individual sPLA2s exhibit unique tissue and cellular localizations and specific enzymatic properties, suggesting distinct biological roles. Individual sPLA2s are involved in diverse biological events through lipid mediator-dependent or -independent processes and act redundantly or non-redundantly in a given microenvironment. In the past few years, new biological aspects of sPLA2s have been clarified using their transgenic and knockout mouse lines in combination with mass spectrometric lipidomics to unveil their target substrates and products in vivo. In the 3rd edition of this review series, we highlight the newest understanding of the in vivo functions of sPLA2s in pathophysiological conditions in the context of immunity and metabolism. We will also describe the latest knowledge on PLA2R1, the best known sPLA2 receptor, which may serve either as a clearance or signaling receptor for sPLA2 or may even act independently of sPLA2 function.
H. Sato, Y. Taketomi, A. Ushida, Y. Isogai, T. Kojima, T. Hirabayashi, Y. Miki, Kei Yamamoto, Y. Nishito, T. Kobayashi, K. Ikeda, R. Taguchi, S. Hara, S. Ida, Y. Miyamoto, M. Watanabe, H. Baba, K. Miyata, Y. Oike, M.H. Gelb and M. Murakami : The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity., Cell Metabolism, Vol.20, No.1, 119-132, 2014.
(Summary)
Metabolic disorders, including obesity and insulin resistance, have their basis in dysregulated lipid metabolism and low-grade inflammation. In a microarray search of unique lipase-related genes whose expressions are associated with obesity, we found that two secreted phospholipase A2s (sPLA2s), PLA2G5 and PLA2G2E, were robustly induced in adipocytes of obese mice. Analyses of Pla2g5(-/-) and Pla2g2e(-/-) mice revealed distinct roles of these sPLA2s in diet-induced obesity. PLA2G5 hydrolyzed phosphatidylcholine in fat-overladen low-density lipoprotein to release unsaturated fatty acids, which prevented palmitate-induced M1 macrophage polarization. As such, PLA2G5 tipped the immune balance toward an M2 state, thereby counteracting adipose tissue inflammation, insulin resistance, hyperlipidemia, and obesity. PLA2G2E altered minor lipoprotein phospholipids, phosphatidylserine and phosphatidylethanolamine, and moderately facilitated lipid accumulation in adipose tissue and liver. Collectively, the identification of "metabolic sPLA2s" adds this gene family to a growing list of lipolytic enzymes that act as metabolic coordinators.
(Keyword)
Adipose Tissue, White / Animals / Cells, Cultured / Diet, High-Fat / Female / Glucose Tolerance Test / Group II Phospholipases A2 / Group V Phospholipases A2 / Humans / Inflammation / Insulin / Leptin / Lipoproteins / Liver / Macrophages / Mice / Mice, Inbred C57BL / Mice, Knockout / Mice, Obese / Obesity / Proto-Oncogene Proteins c-akt / RNA, Messenger / Time Factors
Y. Miki, Kei Yamamoto, Y. Taketomi, H. Sato, K. Shimo, T. Kobayashi, Y. Ishikawa, T. Ishii, H. Nakanishi, K. Ikeda, R. Taguchi, K. Kabashima, M. Arita, H. Arai, G. Lambeau, J.M. Bollinger, S. Hara, M.H. Gelb and M. Murakami : Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving anti-inflammatory lipid mediators., The Journal of Experimental Medicine, Vol.210, 1217-1234, 2013.
(Summary)
Resolution of inflammation is an active process that is mediated in part by antiinflammatory lipid mediators. Although phospholipase A2 (PLA2) enzymes have been implicated in the promotion of inflammation through mobilizing lipid mediators, the molecular entity of PLA2 subtypes acting upstream of antiinflammatory lipid mediators remains unknown. Herein, we show that secreted PLA2 group IID (PLA2G2D) is preferentially expressed in CD11c(+) dendritic cells (DCs) and macrophages and displays a pro-resolving function. In hapten-induced contact dermatitis, resolution, not propagation, of inflammation was compromised in skin and LNs of PLA2G2D-deficient mice (Pla2g2d(-/-)), in which the immune balance was shifted toward a proinflammatory state over an antiinflammatory state. Bone marrow-derived DCs from Pla2g2d(-/-) mice were hyperactivated and elicited skin inflammation after intravenous transfer into mice. Lipidomics analysis revealed that PLA2G2D in the LNs contributed to mobilization of a pool of polyunsaturated fatty acids that could serve as precursors for antiinflammatory/pro-resolving lipid mediators such as resolvin D1 and 15-deoxy-Δ(12,14)-prostaglandin J2, which reduced Th1 cytokine production and surface MHC class II expression in LN cells or DCs. Altogether, our results highlight PLA2G2D as a "resolving sPLA2" that ameliorates inflammation through mobilizing pro-resolving lipid mediators and points to a potential use of this enzyme for treatment of inflammatory disorders.
Y. Taketomi, N. Ueno, T. Kojima, H. Sato, R. Murase, Kei Yamamoto, S. Tanaka, M. Sakanaka, M. Nakamura, Y. Nishito, M. Kawana, N. Kambe, K. Ikeda, R. Taguchi, S. Nakamizo, K. Kabashima, M.H. Gelb, M. Arita, T. Yokomizo, M. Nakamura, K. Watanabe, H. Hirai, M. Nakamura, Y. Okayama, C. Ra, K. Aritake, Y. Urade, K. Morimoto, Y. Sugimoto, T. Shimizu, S. Narumiya, S. Hara and M. Murakami : Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis., Nature Immunology, Vol.14, No.6, 554-563, 2013.
(Summary)
Microenvironment-based alterations in phenotypes of mast cells influence the susceptibility to anaphylaxis, yet the mechanisms underlying proper maturation of mast cells toward an anaphylaxis-sensitive phenotype are incompletely understood. Here we report that PLA2G3, a mammalian homolog of anaphylactic bee venom phospholipase A2, regulates this process. PLA2G3 secreted from mast cells is coupled with fibroblastic lipocalin-type PGD2 synthase (L-PGDS) to provide PGD2, which facilitates mast-cell maturation via PGD2 receptor DP1. Mice lacking PLA2G3, L-PGDS or DP1, mast cell-deficient mice reconstituted with PLA2G3-null or DP1-null mast cells, or mast cells cultured with L-PGDS-ablated fibroblasts exhibited impaired maturation and anaphylaxis of mast cells. Thus, we describe a lipid-driven PLA2G3-L-PGDS-DP1 loop that drives mast cell maturation.
H. Ait-Oufella, O. Herbin, C. Lahoute, C. Coatrieux, X. Loyer, J. Joffre, L. Laurans, B. Ramkhelawon, O. Blanc-Brude, S. Karabina, C.A. Girard, C. Payré, Kei Yamamoto, C.J. Binder, M. Murakami, A. Tedgui, G. Lambeau and Z. Mallat : Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice: GX sPLA2 reduces atherosclerosis., Arteriosclerosis, Thrombosis, and Vascular Biology, Vol.33, 466-473, 2013.
N. Ueno, Y. Taketomi, Kei Yamamoto, T. Hirabayashi, D. Kamei, Y. Kita, T. Shimizu, K. Shinzawa, Y. Tsujimoto, K. Ikeda, R. Taguchi and M. Murakami : Analysis of two major intracellular phospholipase A2s in mast cells reveals crucial contribution of cPLA2a, not iPLA2b, to lipid mobilization in proximal mast cells and distal fibroblasts., The Journal of Biological Chemistry, Vol.286, No.43, 37249-37263, 2011.
(Summary)
Mast cells release a variety of mediators, including arachidonic acid (AA) metabolites, to regulate allergy, inflammation, and host defense, and their differentiation and maturation within extravascular microenvironments depend on the stromal cytokine stem cell factor. Mouse mast cells express two major intracellular phospholipases A(2) (PLA(2)s), namely group IVA cytosolic PLA(2) (cPLA(2)α) and group VIA Ca(2+)-independent PLA(2) (iPLA(2)β), and the role of cPLA(2)α in eicosanoid synthesis by mast cells has been well documented. Lipidomic analyses of mouse bone marrow-derived mast cells (BMMCs) lacking cPLA(2)α (Pla2g4a(-/-)) or iPLA(2)β (Pla2g6(-/-)) revealed that phospholipids with AA were selectively hydrolyzed by cPLA(2)α, not by iPLA(2)β, during FcϵRI-mediated activation and even during fibroblast-dependent maturation. Neither FcϵRI-dependent effector functions nor maturation-driven phospholipid remodeling was impaired in Pla2g6(-/-) BMMCs. Although BMMCs did not produce prostaglandin E(2) (PGE(2)), the AA released by cPLA(2)α from BMMCs during maturation was converted to PGE(2) by microsomal PGE synthase-1 (mPGES-1) in cocultured fibroblasts, and accordingly, Pla2g4a(-/-) BMMCs promoted microenvironmental PGE(2) synthesis less efficiently than wild-type BMMCs both in vitro and in vivo. Mice deficient in mPGES-1 (Ptges(-/-)) had an augmented local anaphylactic response. These results suggest that cPLA(2)α in mast cells is functionally coupled, through the AA transfer mechanism, with stromal mPGES-1 to provide anti-anaphylactic PGE(2). Although iPLA(2)β is partially responsible for PGE(2) production by macrophages and dendritic cells, it is dispensable for mast cell maturation and function.
(Keyword)
Anaphylaxis / Animals / Arachidonic Acid / Bone Marrow Cells / Cells, Cultured / Coculture Techniques / Dinoprostone / Fibroblasts / Group IV Phospholipases A2 / Group VI Phospholipases A2 / Intramolecular Oxidoreductases / Mast Cells / Mice / Mice, Knockout / Phospholipids
M. Murakami, Y. Taketomi, H. Sato and Kei Yamamoto : Phospholipase A2 revisited., The Journal of Biochemistry, Vol.150, No.3, 233-255, 2011.
(Summary)
Phospholipase A(2) (PLA(2)) catalyses the hydrolysis of the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids. So far, more than 30 enzymes that possess PLA(2) or related activity have been identified in mammals. About one third of these enzymes belong to the secreted PLA(2) (sPLA(2)) family, which comprises low molecular weight, Ca(2+) requiring, secreted enzymes with a His/Asp catalytic dyad. Individual sPLA(2)s display distinct localizations and enzymatic properties, suggesting their specialized biological roles. However, in contrast to intracellular PLA(2)s, whose roles in signal transduction and membrane homoeostasis have been well documented, the biological roles of sPLA(2)s in vivo have remained obscure until recently. Over the past decade, information fuelled by studies employing knockout and transgenic mice as well as specific inhibitors, in combination with lipidomics, has clarified when and where the different sPLA(2) isoforms are expressed, which isoforms are involved in what types of pathophysiology, and how they exhibit their specific functions. In this review, we highlight recent advances in PLA(2) research, focusing mainly on the physiological functions of sPLA(2)s and their modes of action on 'extracellular' phospholipid targets versus lipid mediator production.
Kei Yamamoto, Y. Isogai, H. Sato, Y. Taketomi and M. Murakami : Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics., Analytical and Bioanalytical Chemistry, Vol.400, No.7, 1829-1842, 2011.
(Summary)
Phospholipase A(2) (PLA(2)) is a group of enzymes that hydrolyze the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids. Of many PLA(2)s or related enzymes identified to date, secreted PLA(2)s (sPLA(2)s) comprise the largest family that contains 10 catalytically active isozymes. Besides arachidonic acid released from cellular membranes for eicosanoid synthesis, several if not all sPLA(2)s have recently been implicated in hydrolysis of phospholipids in lipoprotein particles. The sPLA(2)-processed low-density lipoprotein (LDL) particles contain a large amount of lysophospholipids and exhibit the property of "small-dense" or "modified" LDL, which facilitates foam cell formation from macrophages. Transgenic overexpression of these sPLA(2)s leads to development of atherosclerosis in mice. More importantly, genetic deletion or pharmacological inhibition of particular sPLA(2)s significantly attenuates atherosclerosis and aneurysm. In this article, we will give an overview of current understanding of the role of sPLA(2)s in atherosclerosis, with recent lipidomics data showing the action of a subset of sPLA(2)s on lipoprotein phospholipids.
M. Murakami, Y. Taketomi, H. Sato and Kei Yamamoto : Integrated lipidomics in the secreted phospholipase A2 biology., International Journal of Molecular Sciences, Vol.12, No.3, 1474-1495, 2011.
(Summary)
Mammalian genomes encode genes for more than 30 phospholipase A(2)s (PLA(2)s) or related enzymes, which are subdivided into several subgroups based on their structures, catalytic mechanisms, localizations and evolutionary relationships. More than one third of the PLA(2) enzymes belong to the secreted PLA(2) (sPLA(2)) family, which consists of low-molecular-weight, Ca(2+)-requiring extracellular enzymes, with a His-Asp catalytic dyad. Individual sPLA(2) isoforms exhibit unique tissue and cellular localizations and enzymatic properties, suggesting their distinct pathophysiological roles. Recent studies using transgenic and knockout mice for several sPLA(2) isoforms, in combination with lipidomics approaches, have revealed their distinct contributions to various biological events. Herein, we will describe several examples of sPLA(2)-mediated phospholipid metabolism in vivo, as revealed by integrated analysis of sPLA(2) transgenic/knockout mice and lipid mass spectrometry. Knowledge obtained from this approach greatly contributes to expanding our understanding of the sPLA(2) biology and pathophysiology.
(Keyword)
Alopecia / Animals / Atherosclerosis / Cell Membrane / Epididymis / Genital Diseases, Male / Lung / Male / Phospholipases A2, Secretory / Protein Isoforms
H. Sato, Y. Isogai, S. Masuda, Y. Taketomi, Y. Miki, D. Kamei, S. Hara, T. Kobayashi, Y. Ishikawa, T. Ishii, K. Ikeda, R. Taguchi, Y. Ishimoto, N. Suzuki, Y. Yokota, K. Hanasaki, T. Suzuki-Yamamoto, Kei Yamamoto and M. Murakami : Physiological roles of group X secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function., The Journal of Biological Chemistry, Vol.286, No.13, 11632-11648, 2011.
(Summary)
Although the secreted phospholipase A(2) (sPLA(2)) family has been generally thought to participate in pathologic events such as inflammation and atherosclerosis, relatively high and constitutive expression of group X sPLA(2) (sPLA(2)-X) in restricted sites such as reproductive organs, the gastrointestinal tract, and peripheral neurons raises a question as to the roles played by this enzyme in the physiology of reproduction, digestion, and the nervous system. Herein we used mice with gene disruption or transgenic overexpression of sPLA(2)-X to clarify the homeostatic functions of this enzyme at these locations. Our results suggest that sPLA(2)-X regulates 1) the fertility of spermatozoa, not oocytes, beyond the step of flagellar motility, 2) gastrointestinal phospholipid digestion, perturbation of which is eventually linked to delayed onset of a lean phenotype with reduced adiposity, decreased plasma leptin, and improved muscle insulin tolerance, and 3) neuritogenesis of dorsal root ganglia and the duration of peripheral pain nociception. Thus, besides its inflammatory action proposed previously, sPLA(2)-X participates in physiologic processes including male fertility, gastrointestinal phospholipid digestion linked to adiposity, and neuronal outgrowth and sensing.
Kei Yamamoto, Y. Taketomi, Y. Isogai, Y. Miki, H. Sato, S. Masuda, Y. Nishito, K. Morioka, Y. Ishimoto, N. Suzuki, Y. Yokoya, K. Hanasaki, Y. Ishikawa, T. Ishii, T. Kobayashi, K. Fukami, K. Ikeda, H. Nakanishi, R. Taguchi and M. Murakami : Hair follicular expression and function of group X secreted phospholipase A2 in mouse skin., The Journal of Biological Chemistry, Vol.286, No.13, 11616-11631, 2011.
(Summary)
Although perturbed lipid metabolism can often lead to skin abnormality, the role of phospholipase A(2) (PLA(2)) in skin homeostasis is poorly understood. In the present study we found that group X-secreted PLA(2) (sPLA(2)-X) was expressed in the outermost epithelium of hair follicles in synchrony with the anagen phase of hair cycling. Transgenic mice overexpressing sPLA(2)-X (PLA2G10-Tg) displayed alopecia, which was accompanied by hair follicle distortion with reduced expression of genes related to hair development, during a postnatal hair cycle. Additionally, the epidermis and sebaceous glands of PLA2G10-Tg skin were hyperplasic. Proteolytic activation of sPLA(2)-X in PLA2G10-Tg skin was accompanied by preferential hydrolysis of phosphatidylethanolamine species with polyunsaturated fatty acids as well as elevated production of some if not all eicosanoids. Importantly, the skin of Pla2g10-deficient mice had abnormal hair follicles with noticeable reduction in a subset of hair genes, a hypoplasic outer root sheath, a reduced number of melanin granules, and unexpected up-regulation of prostanoid synthesis. Collectively, our study highlights the spatiotemporal expression of sPLA(2)-X in hair follicles, the presence of skin-specific machinery leading to sPLA(2)-X activation, a functional link of sPLA(2)-X with hair follicle homeostasis, and compartmentalization of the prostanoid pathway in hair follicles and epidermis.
M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi and Kei Yamamoto : Recent progress in phospholipase A2 research: from cells to animals to humans., Progress in Lipid Research, Vol.50, No.2, 152-192, 2011.
(Summary)
Mammalian genomes encode genes for more than 30 phospholipase A2s (PLA2s) or related enzymes, which are subdivided into several classes including low-molecular-weight secreted PLA2s (sPLA2s), Ca²+-dependent cytosolic PLA2s (cPLA2s), Ca²+-independent PLA2s (iPLA2s), platelet-activating factor acetylhydrolases (PAF-AHs), lysosomal PLA2s, and a recently identified adipose-specific PLA. Of these, the intracellular cPLA2 and iPLA2 families and the extracellular sPLA2 family are recognized as the "big three". From a general viewpoint, cPLA2 (the prototypic cPLA2 plays a major role in the initiation of arachidonic acid metabolism, the iPLA2 family contributes to membrane homeostasis and energy metabolism, and the sPLA2 family affects various biological events by modulating the extracellular phospholipid milieus. The cPLA2 family evolved along with eicosanoid receptors when vertebrates first appeared, whereas the diverse branching of the iPLA2 and sPLA2 families during earlier eukaryote development suggests that they play fundamental roles in life-related processes. During the past decade, data concerning the unexplored roles of various PLA2 enzymes in pathophysiology have emerged on the basis of studies using knockout and transgenic mice, the use of specific inhibitors, and information obtained from analysis of human diseases caused by mutations in PLA2 genes. This review focuses on current understanding of the emerging biological functions of PLA2s and related enzymes.
J. Escoffier, I. Jemel, A. Tanemoto, Y. Taketomi, C. Payre, C. Coatrieux, H. Sato, Kei Yamamoto, S. Masuda, K. Pernet-Gallay, V. Pierre, S. Hara, M. Murakami, M.D. Waard, G. Lambeau and C. Arnoult : Group X phospholipase A2 is released during sperm acrosome reaction and controls fertility outcome in mice., The Journal of Clinical Investigation, Vol.120, No.5, 1415-1428, 2010.
(Summary)
Ejaculated mammalian sperm must undergo a maturation process called capacitation before they are able to fertilize an egg. Several studies have suggested a role for members of the secreted phospholipase A2 (sPLA2) family in capacitation, acrosome reaction (AR), and fertilization, but the molecular nature of these enzymes and their specific roles have remained elusive. Here, we have demonstrated that mouse group X sPLA2 (mGX) is the major enzyme present in the acrosome of spermatozoa and that it is released in an active form during capacitation through spontaneous AR. mGX-deficient male mice produced smaller litters than wild-type male siblings when crossed with mGX-deficient females. Further analysis revealed that spermatozoa from mGX-deficient mice exhibited lower rates of spontaneous AR and that this was associated with decreased in vitro fertilization (IVF) efficiency due to a drop in the fertilization potential of the sperm and an increased rate of aborted embryos. Treatment of sperm with sPLA2 inhibitors and antibodies specific for mGX blocked spontaneous AR of wild-type sperm and reduced IVF success. Addition of lysophosphatidylcholine, a catalytic product of mGX, overcame these deficiencies. Finally, recombinant mGX triggered AR and improved IVF outcome. Taken together, our results highlight a paracrine role for mGX during capacitation in which the enzyme primes sperm for efficient fertilization and boosts premature AR of a likely phospholipid-damaged sperm subpopulation to eliminate suboptimal sperm from the pool available for fertilization.
H. Sato, Y. Taketomi, Y. Isogai, Y. Miki, Kei Yamamoto, S. Masuda, T. Hosono, S. Arata, Y. Ishikawa, T. Ishii, T. Kobayashi, H. Nakanishi, K. Ikeda, R. Taguchi, S. Hara, I. Kudo and M. Murakami : Group III secreted phospholipase A2 regulates epididymal sperm maturation and fertility., The Journal of Clinical Investigation, Vol.120, No.5, 1400-1414, 2010.
(Summary)
Although lipid metabolism is thought to be important for the proper maturation and function of spermatozoa, the molecular mechanisms that underlie this dynamic process in the gonads remains incompletely understood. Here, we show that group III phospholipase A2 (sPLA2-III), a member of the secreted phospholipase A2 (sPLA2) family, is expressed in the mouse proximal epididymal epithelium and that targeted disruption of the gene encoding this protein (Pla2g3) leads to defects in sperm maturation and fertility. Although testicular spermatogenesis in Pla2g3-/- mice was grossly normal, spermatozoa isolated from the cauda epididymidis displayed hypomotility, and their ability to fertilize intact eggs was markedly impaired. Transmission EM further revealed that epididymal spermatozoa in Pla2g3-/- mice had both flagella with abnormal axonemes and aberrant acrosomal structures. During epididymal transit, phosphatidylcholine in the membrane of Pla2g3+/+ sperm underwent a dramatic shift in its acyl groups from oleic, linoleic, and arachidonic acids to docosapentaenoic and docosahexaenoic acids, whereas this membrane lipid remodeling event was compromised in sperm from Pla2g3-/- mice. Moreover, the gonads of Pla2g3-/- mice contained less 12/15-lipoxygenase metabolites than did those of Pla2g3+/+ mice. Together, our results reveal a role for the atypical sPLA2 family member sPLA2-III in epididymal lipid homeostasis and indicate that its perturbation may lead to sperm dysfunction.
M. Murakami, Y. Taketomi, G. Girard, Kei Yamamoto and G. Lambeau : Emerging roles of secreted phospholipase A2 enzymes: lessons from transgenic and knockout mice., Biochimie, Vol.92, No.6, 561-582, 2010.
(Summary)
Among the emerging phospholipase A(2) (PLA(2)) superfamily, the secreted PLA(2) (sPLA(2)) family consists of low-molecular-mass, Ca(2+)-requiring extracellular enzymes with a His-Asp catalytic dyad. To date, more than 10 sPLA(2) enzymes have been identified in mammals. Individual sPLA(2)s exhibit unique tissue and cellular localizations and enzymatic properties, suggesting their distinct pathophysiological roles. Despite numerous enzymatic and cell biological studies on this enzyme family in the past two decades, their precise in vivo functions still remain largely obscure. Recent studies using transgenic and knockout mice for several sPLA(2) enzymes, in combination with lipidomics approaches, have opened new insights into their distinct contributions to various biological events such as food digestion, host defense, inflammation, asthma and atherosclerosis. In this article, we overview the latest understanding of the pathophysiological functions of individual sPLA(2) isoforms fueled by studies employing transgenic and knockout mice for several sPLA(2)s.
Y. Ishikawa, M. Kimura-Matsumoto, M. Murakami, Kei Yamamoto, Y. Akasaka, M. Uzuki, Y. Yuri, N. Inomata, T. Yokoo and T. Ishii : Distribution of smooth muscle cells and macrophages expressing scavenger receptor Bi/II in atherosclerosis., Journal of Atherosclerosis and Thrombosis, Vol.16, No.6, 829-839, 2009.
(Summary)
Scavenger receptors type I and II (SRBI/II) have dual roles in both atherogenic and antiatherogenic functions through interactions with lipoproteins and their expression in macrophages; how-ever, the distribution and density of SRBI/II-positive macrophages and smooth muscle cells (SMCs) as well as their association with lipid metabolism-related proteins in atherosclerotic intima of the human aorta remain unclear. Autopsied aortic tissues were double-immunostained with SRBI/BII and smooth muscle actin or macrophage-specific antibodies. The density of SRBI/BII-positive SMCs and macrophages in intimal lesion was measured. They were also immunostained with antibodies against four apolipoproteins, four phospholipase A2s, and CETP. SRBI/II was expressed in both macrophages and SMCs distributed in various intimal lesions. The density of SRBI/II-positive SMCs in intimal lesions significantly decreased with the advance of atherosclerosis, whereas the density of SRBI/II-positive macrophages significantly increased with atherosclerotic development. In addition, functional proteins, such as apolipoproteins, secretory phospholipase A2s, and CETP, were distributed in the intimal stroma around SRBI/II-positive cells in all lesion types. The results indicated that SMCs are involved in lipid metabolism via SRBI/II expression mainly in the early stages of atherosclerosis evolution, and that SRBI/II-positive macrophages are mainly involved in advanced stages.
(Keyword)
Adult / Aged / Aged, 80 and over / Aorta / Apolipoproteins / Atherosclerosis / Autopsy / Female / Humans / Lysosome-Associated Membrane Glycoproteins / Macrophages / Male / Middle Aged / Myocytes, Smooth Muscle / Receptors, Scavenger / Scavenger Receptors, Class B
H. Sato, Y. Taketomi, Y. Isogai, S. Masuda, T. Kobayashi, Kei Yamamoto and M. Murakami : Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation., The Biochemical Journal, Vol.421, No.1, 17-27, 2009.
(Summary)
PLA2 (phospholipase A2) group III is an atypical sPLA2 (secretory PLA2) that is homologous with bee venom PLA2 rather than with other mammalian sPLA2s. In the present paper, we show that endogenous group III sPLA2 (PLA2G3) is expressed in mouse skin and that Tg (transgenic) mice overexpressing human PLA2G3 spontaneously develop skin inflammation. Pla2g3-Tg mice over 9 months of age frequently developed dermatitis with hyperkeratosis, acanthosis, parakeratosis, erosion, ulcer and sebaceous gland hyperplasia. The dermatitis was accompanied by infiltration of neutrophils and macrophages and by elevated levels of pro-inflammatory cytokines, chemokines and prostaglandin E2. In addition, Pla2g3-Tg mice had increased lymph aggregates and mucus in the airway, lymphocytic sialadenitis, hepatic extramedullary haemopoiesis, splenomegaly with increased populations of granulocytes and monocytes/macrophages, and increased serum IgG1. Collectively, these observations provide the first demonstration of spontaneous development of inflammation in mice with Tg overexpression of mammalian sPLA2.
H. Sato, R. Kato, Y. Isogai, G. Saka, M. Ohtsuki, Y. Takketomi, Kei Yamamoto, K. Tsutsumi, J. Yamada, S. Masuda, Y. Ishikawa, T. Ishii, T. Kobayashi, K. Ikeda, R. Taguchi, S. Hatakeyama, S. Hara, I. Kudo, H. Itabe and M. Murakami : Analyses of group III secreted phospholipase A2 transgenic mice reveals potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis., The Journal of Biological Chemistry, Vol.283, No.48, 33483-33497, 2008.
(Summary)
Among the many mammalian secreted phospholipase A2 (sPLA2) enzymes, PLA2G3 (group III secreted phospholipase A2) is unique in that it possesses unusual N- and C-terminal domains and in that its central sPLA2 domain is homologous to bee venom PLA2 rather than to other mammalian sPLA2s. To elucidate the in vivo actions of this atypical sPLA2, we generated transgenic (Tg) mice overexpressing human PLA2G3. Despite marked increases in PLA2 activity and mature 18-kDa PLA2G3 protein in the circulation and tissues, PLA2G3 Tg mice displayed no apparent abnormality up to 9 months of age. However, alterations in plasma lipoproteins were observed in PLA2G3 Tg mice compared with control mice. In vitro incubation of low density (LDL) and high density (HDL) lipoproteins with several sPLA2s showed that phosphatidylcholine was efficiently converted to lysophosphatidylcholine by PLA2G3 as well as by PLA2G5 and PLA2G10, to a lesser extent by PLA2G2F, and only minimally by PLA2G2A and PLA2G2E. PLA2G3-modified LDL, like PLA2G5- or PLA2G10-treated LDL, facilitated the formation of foam cells from macrophages ex vivo. Accumulation of PLA2G3 was detected in the atherosclerotic lesions of humans and apoE-deficient mice. Furthermore, following an atherogenic diet, aortic atherosclerotic lesions were more severe in PLA2G3 Tg mice than in control mice on the apoE-null background, in combination with elevated plasma lysophosphatidylcholine and thromboxane A2 levels. These results collectively suggest a potential functional link between PLA2G3 and atherosclerosis, as has recently been proposed for PLA2G5 and PLA2G10.
S. Masuda, Kei Yamamoto, T. Hirabayashi, Y. Ishikawa, T. Ishii, I. Kudo and M. Murakami : Human group III phospholipase A2 promotes neuronal outgrowth and survival., The Biochemical Journal, Vol.409, No.2, 429-438, 2008.
(Summary)
Human sPLA2-III [group III secreted PLA2 (phospholipase A2)] is an atypical sPLA2 isoenzyme that consists of a central group III sPLA2 domain flanked by unique N- and C-terminal domains. In the present study, we found that sPLA2-III is expressed in neuronal cells, such as peripheral neuronal fibres, spinal DRG (dorsal root ganglia) neurons and cerebellar Purkinje cells. Adenoviral expression of sPLA2-III in PC12 cells (pheochromocytoma cells) or DRG explants facilitated neurite outgrowth, whereas expression of a catalytically inactive sPLA2-III mutant or use of sPLA2-III-directed siRNA (small interfering RNA) reduced NGF (nerve growth factor)-induced neuritogenesis. sPLA2-III also suppressed neuronal death induced by NGF deprivation. Lipid MS revealed that sPLA2-III overexpression increased the cellular level of lysophosphatidylcholine, a PLA2 reaction product with neuritogenic and neurotropic activities, whereas siRNA knockdown reduced the level of lysophosphatidylcholine. These observations suggest the potential contribution of sPLA2-III to neuronal differentiation and its function under certain conditions.
M. Ohtsuki, Y. Taketomi, S. Arata, S. Masuda, Y. Ishikawa, T. Ishii, Y. Takanezawa, J. Aoki, H. Arai, Kei Yamamoto, I. Kudo and M. Murakami : Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction., The Journal of Biological Chemistry, Vol.281, No.47, 36420-36433, 2006.
(Summary)
In an effort to elucidate the functions of secreted phospholipase A2 (sPLA2) enzymes in vivo, we generated transgenic (Tg) mice for group V sPLA2 (sPLA2-V) and group X sPLA2 (sPLA2-X), which act potently on phosphatidylcholine in vitro. We found that sPLA2-V Tg mice died in the neonatal period because of respiratory failure. The lungs of sPLA2-V Tg mice exhibited atelectasis with thickened alveolar walls and narrow air spaces, accompanied by infiltration of macrophages and only modest changes in eicosanoid levels. This severe pulmonary defect in sPLA2-V Tg mice was attributable to marked reduction of the lung surfactant phospholipids, phosphatidylcholine and phosphatidylglycerol. Given that the expression of sPLA2-V is greatly elevated in human lungs with severe inflammation, our present results raise the intriguing possibility that this isozyme may contribute to ongoing surfactant hydrolysis often observed in the lungs of patients with respiratory distress syndrome. In contrast, sPLA2-X Tg neonates displayed minimal abnormality of the respiratory tract with normal alveolar architecture and surfactant composition. This unexpected result was likely because sPLA2-X protein existed as an inactive zymogen in most tissues. The active form of sPLA2-X was detected in tissues with inflammatory granulation in sPLA2-X Tg mice. These results suggest that sPLA2-X mostly remains inactive under physiological conditions and that its proteolytic activation occurs during inflammation or other as yet unidentified circumstances in vivo.
(Keyword)
Animals / Female / Gene Expression Regulation, Developmental / Genotype / Group V Phospholipases A2 / Group X Phospholipases A2 / Inflammation / Lung / Lung Diseases / Male / Mice / Mice, Inbred C57BL / Mice, Transgenic / Phosphatidylcholines / Phosphatidylglycerols / Phospholipases A / Phospholipases A2
Kei Yamamoto, J. Wang, S. Yamamoto and H. Tobe : Suppression of cyclooxygenase-2 gene transcription by humulon., Advances in Experimental Medicine and Biology, Vol.507, 73-77, 2002.
K. Kurachi, K. Zhang, J. Huo, A. Ameri, M. Kuwahara, J.-M. Fontaine, Kei Yamamoto and S. Kurachi : Age-related regulation of genes: slow homeostatic changes and age-dimension technology., Physica A: Statistical Mechanics and its Applications, Vol.315, 105-113, 2002.
50.
M. Shimamura, T. Hazato, H. Ashino, Y. Yamamoto, E. Iwasaki, H. Tobe, Kei Yamamoto and S. Yamamoto : Inhibition of angiogenesis by humulone, a bitter acid from beer hop., Biochemical and Biophysical Research Communications, Vol.289, No.1, 220-224, 2001.
(Summary)
On the basis of our previous finding that humulone, a bitter acid from beer hop extract, was a potent inhibitor of bone resorption and inhibited the catalytic activity of cyclooxygenase-2 (COX-2) and more potently the transcription of the COX-2 gene, we examined the effect of humulone on angiogenesis, using chick embryo chorioallantoic membranes (CAMs) and vascular endothelial and tumor cells. Humulone significantly prevented in vivo angiogenesis in CAM in a dose-dependent manner with an ED(50) of 1.5 microg/CAM. Humulone also inhibited in vitro tube formation of vascular endothelial cells. Moreover, it suppressed the proliferation of endothelial cells and the production of vascular endothelial growth factor (VEGF), an angiogenic growth factor, in endothelial and tumor cells. Thus, humulone is a potent angiogenic inhibitor, and may be a novel powerful tool for the therapy of various angiogenic diseases involving solid tumor growth and metastasis.
Kei Yamamoto, J. Wang, Y. Sugimoto, A. Ichikawa and S. Yamamoto : Induction of prostaglandin I2 receptor in murine osteoblastic cell., Advances in Prostaglandin and Leukotriene Research, 103-106, 2001.
52.
K. Tsboi, Y. Sugimoto, A. Iwane, Kei Yamamoto, S. Yamamoto and A. Ichikawa : Uterine expression of prostaglandin H2 synthase in late pregnancy and during parturition in prostaglandin F receptor-deficient mice., Endocrinology, Vol.141, No.1, 315-324, 2000.
(Summary)
PG production in uterine tissues is important for many physiological processes in late pregnancy, including parturition. We examined the expression of the PGH2 synthases, cyclooxygenase-1 (COX-1) and COX-2, in uterine tissues during late pregnancy, using PGF receptor-deficient (FP-/-) mice. Female FP-/- mice are unable to deliver normal fetuses at term, as they do not undergo luteolysis necessary for parturition. In wild-type mice, COX-1 messenger RNA (mRNA) was expressed in the endometrial epithelium, myometrium, and decidua throughout late pregnancy. The expression of COX-1 mRNA in the endometrial epithelium and myometrium decreased both in wild-type mice undergoing natural parturition and in FP-/- mice undergoing ovariectomy-induced parturition, but expression of COX-1 mRNA was enhanced in FP-/- mice at the expected term. In wild-type mice, COX-2 mRNA was not expressed in the myometrium before parturition, but was markedly induced during parturition. This induction of COX-2 was absent in FP-/- mice at the expected term, but was found during ovariectomy-induced parturition in these mice. Expression of COX-2 proteins was confirmed by immunohistochemical analysis. Thus, in uterine tissues, myometrial expression of COX-2 is closely associated with the occurrence of parturition, but uterine expression of COX-1 is induced much earlier and kept at a high level until parturition occurs. These results suggest that COX-1-derived PGs are responsible for the induction of luteolysis, and that COX-2-derived PGs play a role in the final pathway of parturition.
S Yamamoto, N. Ueda, I. Mahmud, H. Yamaguchi, R. Yamashita, Kei Yamamoto, K. Ishimura, Y. Urade, Y. Kanaoka and O. Hayaishi : Fatty acid cyclooxygenase induction accompanied by prostaglandin D synthesis in a human megakaryoblastic cell line CMK differentiated by phorbol ester., BioFactors, Vol.11, 57-61, 2000.
54.
H. Sei, D. Saito, Kei Yamamoto, K. Morita and Y. Morita : Differential effect of short-term REM sleep deprivation on NGF and BDNF protein level in the rat brain., Brain Research, Vol.877, 387-390, 2000.
55.
Kei Yamamoto, J. Wang, S. Yamamoto and H. Tobe : Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid., FEBS Letters, Vol.877, 387-390, 2000.
56.
J. Wang, Kei Yamamoto, Y. Sugimoto, A. Ichikawa and S. Yamamoto : Induction of prostaglandin I2 receptor by tumor necrosis factor-alpha in osteoblastic MC3T3-E1 cells., Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, Vol.1441, 69-76, 1999.
(Summary)
Mouse osteoblastic cells MC3T3-E1 produced prostaglandin E(2) via the reaction of cyclooxygenase-2 enzyme induced by tumor necrosis factor alpha (TNFalpha). Originally, the mRNA level for prostaglandin I(2) receptor (IP) was low in the cells. However, the addition of TNFalpha brought about a marked increase in the IP mRNA with a lag of about 3 h up to an about 8-fold higher level for 24 h. In addition, the induction of IP was supported by a binding experiment of [(3)H]iloprost (a stable analogue of prostaglandin I(2)). The amount of iloprost bound to the TNFalpha-stimulated cell membranes increased to a saturation level around 30 nM. Dexamethasone, cycloheximide and cyclooxygenase inhibitor suppressed the IP mRNA induction. The finding with the latter two compounds suggested a TNFalpha-dependent de novo synthesis of a protein, which is involved in the IP mRNA induction and may be attributed partially to the induced cyclooxygenase-2.
S. Yamamoto, N. Ueda, I. Mahmud, H. Yamaguchi, R. Yamashita, Kei Yamamoto, K. Ishimura, Y. Urade, Y. Kanaoka and O. Hayaishi : Fatty acid cyclooxygenase induction and prostaglandin D synthesis in a human megakaryoblastic cell line CMK differentiated by phorbol ester., Advances in Experimental Medicine and Biology, Vol.469, 17-21, 1999.
58.
S. Yamamoto, Kei Yamamoto, H. Kurobe, R. Yamashita, H. Yamaguchi and N. Ueda : Transcriptional regulation of fatty acid cyclooxygenase-1 and 2., Int. J. Tiss. Reac., Vol.20, 17-22, 1998.
59.
N. Ueda, Y. Kurahashi, Kei Yamamoto and S. Yamamoto : Anandamide amidohydrolase from porcine brain. Partial purification and characterization., Advances in Experimental Medicine and Biology, Vol.407, 323-328, 1997.
60.
Kei Yamamoto, T. Arakawa, Y. Taketani, Y. Takahashi, Y. Hayashi, N. Ueda, S. Yamamoto and M. Kumegawa : TNFa-dependent induction of cyclooxygenase-2 mediated by NFkB and NF-IL6., Advances in Experimental Medicine and Biology, Vol.407, 185-189, 1997.
61.
Natsuo Ueda, Yuko Kurahashi, Kei Yamamoto, Shozo Yamamoto and Takashi Tokunaga : Enzymes for anandamide biosynthesis and metabolism., Journal of Lipid Mediators and Cell Signalling, Vol.14, No.1-3, 57-61, 1996.
(Summary)
Anandamide is an endogenous ligand for cannabinoid receptors. We tried to isolate and purify "anandamide amidohydrolase' which hydrolyzes anandamide to arachidonic acid and ethanolamine. The enzyme activity was found in the microsomal fraction of porcine brain homogenate. The enzyme was solubilized in 1% Triton X-100, and partially purified by hydrophobic chromatography to a specific activity of about 0.3 mumol/min per mg protein (37 degrees C). Apparent K(m) for anandamide was about 60 microM. The enzyme reacted also with ethanolamides of linoleic, oleic, and palmitic acids at lower rates. This enzyme preparation also converted arachidonic acid to anandamide in the presence of 250 mM concentration of ethanolamine. Several lines of evidence including experiments using various inhibitors suggested that the anandamide synthase and amidohydrolase activities were derived from a single enzyme protein.
H Ikawa, Kei Yamamoto, Y Takahashi, N Ueda, Y Hayashi, S Yamamoto, K Ishimura, M Irahara and T Aono : Arachidonate 12-lipoxygenase in porcine anterior pituitary cells; its localization and possible function in gonadotrophs., The Journal of Endocrinology, Vol.148, 33-41, 1996.
(Summary)
Arachidonate 12-lipoxygenase, which oxygenates positions 12 and 13 of arachidonic and linoleic acids, is present in porcine anterior pituitary cells. Colocalization of the 12-lipoxygenase with various pituitary hormones was examined by immunohistochemical double-staining using antibodies against 12-lipoxygenase and various anterior pituitary hormones. Under light microscopy, approximately 7% of the cells producing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were positive for 12-lipoxygenase, whereas the enzyme was detected in less than 2% of the cells producing thyrotrophin, prolactin, growth hormone (GH), and adrenocorticotrophin. In an attempt to examine the participation of 12-lipoxygenase metabolites in pituitary hormone release, we incubated the primary culture of porcine anterior pituitary cells with 12-hydroperoxy-arachidonic acid or 13-hydroperoxy-linoleic acid. Significant stimulation of LH and FSH release by these hydroperoxides was observed at 10 microM in a time-dependent manner. At doses around 10 microM these compounds produced responses of similar magnitude to 1 nM gonadotrophin-releasing hormone (GnRH), but higher concentrations (30 microM) of the compounds were required for GH release. In contrast, 12-hydroxy-arachidonic and 13-hydroxy-linoleic acids were almost ineffective. Furthermore, the gonadotrophin release by 1 nM GnRH was inhibited by nordihydroguaiaretic acid (a lipoxygenase inhibitor) with an IC50 of about 5 microM. Thus, the hydroperoxy (but not hydroxy) products of 12-lipoxygenase may be involved in the release of pituitary hormones especially LH and FSH.
Y. Harada, K. Hatanaka, M. Kawamura, M. Saito, M. Ogino, M. Majima, T. Ohno, K. Ogino, Kei Yamamoto, Y. Taketani, S. Yamamoto and M. Katori : Role of prostaglandin H synthase-2 in prostaglandin E2 formation in rat carrageenin-induced pleurisy., Prostaglandins, Vol.51, 19-33, 1996.
64.
T. Katagi, H. Kataoka, Y. Konishi, Y. Takata, S. Kitano, M. Yamaki, T. Inoi, Kei Yamamoto, S. Yamamoto and Y. Yamagata : Syntheses and anti-inflammatory activities of O-acyloximes. II., Chem. Pharm. Bull., Vol.44, 145-149, 1996.
65.
N. Ueda, Kei Yamamoto, Y. Kurahashi, S. Yamamoto, M. Ogawa, N. Matsuki, I. Kudo, H. Shinkai, E. Shirakawa and T. Tokunaga : Oxygenation of arachidonylethanolamide (anandamide) by lipoxygenases., Adv. Prostaglandin Thromboxane Leukot. Res., Vol.23, 163-165, 1995.
66.
Kei Yamamoto, T. Arakawa, N. Ueda and S. Yamamoto : Transcriptional roles of nuclear factor B and nuclear factor- interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells., The Journal of Biological Chemistry, Vol.270, 31315-31320, 1995.
67.
N. Ueda, Kei Yamamoto, S. Yamamoto, T. Tokunaga, E. Shirakawa, H. Shinkai, M. Ogawa, T. Sato, I. Kudo, K. Inoue, H. Takizawa, T. Nagano, M. Hirobe, N. Matsuki and H. Saito : Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist., Biochim. Biophys. Acta, Vol.1254, 127-134, 1995.
68.
T. Ohtsuki, M. Matsumoto, Y. Hayashi, Kei Yamamoto, K. Kitagawa, S. Ogawa, S. Yamamoto and T. Kamada : Reperfusion induces 5-lipoxygenase translocation and leukotriene C4 production in ischemic brain., Am. J. Physiol., Vol.268, H1249-H1257, 1995.
Academic Paper (Unrefereed Paper):
1.
Niki Hirabayashi, Tomohito Amano, 三木 寿美, 武市 拓也, 秋山 真志, 村上 誠 and Kei Yamamoto : sPLA2-IIF/P-LPE経路はアトピー性皮膚炎を制御する, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.65, 118-119, 2023.
2.
Akari Fukuta, 重永 章, Haruna Taniguchi, Honami Inubushi, Tomohito Amano, 三木 寿美, 村上 誠 and Kei Yamamoto : sPLA2-IIFの二次産物であるアセタール型リゾプラズマローゲンは創傷治癒を改善する, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.64, 267-269, 2022.
3.
長崎 祐樹, 川井 恵梨佳, 丸岡 紗也, 大角 美穂, 津嘉山 泉, 川上 祐生, 高橋 吉孝, 岡崎 愉加, 三木 寿美, Kei Yamamoto, 村上 誠 and 山本 登志子 : ヒトとウシの乳汁中脂質プロファイル比較, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.63, 142-143, 2021.
4.
宇山 徹, Mustafiz Sultana Brinte Smriti, 森戸 克弥, 高橋 尚子, 川合 克久, Hussain Zahir, 坪井 一人, 荒木 伸一, Kei Yamamoto, 田中 保 and 上田 夏生 : N-アシル-ホスファチジルエタノールアミンの生成におけるcPLA2eの細胞内基質の検討．, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.62, 63-66, 2020.
5.
Kei Yamamoto, Haruka Hakoi, 三木 寿美 and 村上 誠 : IIF型分泌性ホスホリパーゼA2/リゾプラズマローゲン経路は表皮肥厚性疾患の新規創薬ターゲットである, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.61, 57-58, 2019.
6.
戸田 圭祐, 津嘉山 泉, 長崎 祐樹, 爲延 麻子, 鴻池 優佳, 我如古 菜月, 伊東 秀之, 川上 祐生, 高橋 吉孝, 三木 寿美, Kei Yamamoto, 村上 誠 and 山本 登志子 : 赤米由来プロアントシアニジンによる5-リポキシゲナーゼ阻害と乾癬予防効果, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.61, 74-75, 2019.
7.
入江 敦, Kei Yamamoto, 三木 寿美, 武富 芳隆 and 村上 誠 : 破骨細胞における膜リン脂質の代謝動態:PEの合成・輸送・分解と膜融合, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.59, 79-80, 2017.
8.
山本 登志子, 川井 恵梨佳, 田中 充樹, 長崎 祐樹, 戸田 圭祐, 川上 祐生, 高橋 吉孝, 木本 眞順美, Kei Yamamoto and 村上 誠 : ウシ生乳中リポカリン型プロスタグランジンD合成酵素の精製と酵素学的性質ならびに乳房炎のバイオマーカーとしての検討, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.59, 26-28, 2017.
9.
三木 寿美, 城戸 口優, Kei Yamamoto and 村上 誠 : 炎症および癌病態におけるIID型sPLA2の二面的役割, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.58, 114-116, 2016.
10.
Kei Yamamoto, 三木 寿美, 佐藤 弘泰, 武富 芳隆 and 村上 誠 : 皮膚の恒常性と病態における二種のsPLA2の発現と機能, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.58, 117-118, 2016.
11.
武富 芳隆, 砂川 アンナ, 入江 敦, 三木 寿美, Kei Yamamoto, 佐藤 弘泰, 小林 哲幸 and 村上 誠 : マスト細胞を制御する第二のAnaphylatic sPLA2の同定, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.58, 119-121, 2016.
12.
Kei Yamamoto, 三木 寿美 and 村上 誠 : IIF型分泌性ホスホリパーゼA2により産生されるアルケニル型リゾホスファチジルエタノールアミンは表皮肥厚性疾患のバイオマーカーである, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.57, 136-137, 2015.
13.
武富 芳隆, 遠藤 由妃, Kei Yamamoto, 小林 哲幸 and 村上 誠 : Ⅲ型ホスホリパーゼA2は皮膚バリア恒常性に関わる, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.57, 138-139, 2015.
14.
入江 敦, Kei Yamamoto and 村上 誠 : リン脂質動態に基づく破骨細胞融合機構の解明, Proceedings of the Japanese Conference on the Biochemistry of Lipids, Vol.57, 189-190, 2015.
Kei Yamamoto, A. Shiganaga, Haruna Taniguchi, Tomohito Amano, Niki Hirabayashi, Y. Miki and M. Murakami : Acetal-type lysoplasmalogen, a secondary product of group IIF phospholipase A2, improves wound healing, 17th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases, New Orleans, Oct. 2022.
2.
Kei Yamamoto, Haruka Hakoi, Yoshimi Miki and Makoto Murakami : Group IIF phospholipase A2/lysophosplasmalogen axis is a novel drug target for epidermal-hyperplastic diseases., 60th International Conference on the Bioscience of Lipids., Tokyo, Jun. 2019.
3.
K. Toda, Y. Nagasaki, I. Tsukayama, A. Tanenobu, Y. Konoike, N. Ganeko, H. Ito, Y. Kawakami, Y. Yakanashi, Y. Miki, Kei Yamamoto, M. Murakami and T. Suzuki-Yamamoto : Inhibition of arachidonate 5-lipoxygenase and improvement in psoriasis by red rice proanthocyanidin., 60th International Conference on the Bioscience of Lipids, Tokyo, Jun. 2019.
4.
L. Liang, K. Heike, T. Kobayashi, T. Hirabayashi, Y. Miki, Kei Yamamoto, Y. Taketomi and M. Murakami : Group IVE phospholipase A2 (cPLA2e) mobilizes the non-canonical lipid mediator N-acylethanolamine in mouse skin., 60th International Conference on the Bioscience of Lipids, Tokyo, Jun. 2019.
5.
R. Murase, Y. Taketomi, Y. Miki, Kei Yamamoto and M. Murakami : Distinct roles of phospholipase A2s in colitis and colonic cancer., 60th International Conference on the Bioscience of Lipids, Tokyo, Jun. 2019.
6.
H. Sato, Y. Taketomi, Y. Miki, Kei Yamamoto and M. Murakami : Group IID phospholipase A2 promotes browning of white adipose tissue and limits obesity., 60th International Conference on the Bioscience of Lipids, Tokyo, Jun. 2019.
7.
Y. Miki, Y. Taketomi, Kei Yamamoto, K. Hosomi, J. Kunisawa, S.G.B Gowda, K. Ikeda, M. Arita and M. Murakami : Group IIA phospholipase A2 regulates gut microbiome., 60th International Conference on the Bioscience of Lipids, Tokyo, Jun. 2019.
8.
K. Kudou, Y. Miki, H. Higuchi, Kei Yamamoto, M. Murakami and A. Kotani : Exosome could be the source of lipid mediator in cancer platform., 60th International Conference on the Bioscience of Lipids, Tokyo, Jun. 2019.
9.
Haruka Hakoi and Kei Yamamoto : The roles of lysoplasmalogen in three-dimensional keratinocyte culture system, 60th International Conference on the Bioscience of Lipids, Tokyo, Jun. 2019.
10.
Kei Yamamoto, N Higashizaka, S Fujino, Y Miki and M Murakami : A plasmalogen-lysophosphatidylethanolamine produced by epidermal sPLA2 (PLA2G2F) is a novel regulator and drug target for epidermal-hyperplasic diseases., Bioactive Lipids 2018, Athens, Greece, Mar. 2018.
11.
Kei Yamamoto, S. Fujino, Y. Miki and M. Murakami : An epidermal sPLA2 (PLA2G2F)/plasmalogen-lysophosphatidylethanolamine axis is a novel drug target for epidermal-hyperplastic diseases., The 15th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases., Oct. 2017.
12.
Y. Miki, Y. Taketomi, Kei Yamamoto and M. Murakami : Dual roles of group IID phospholipase A2 in inflammation and cancer., The 15th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases., Puerto Vallarta, Mexico, Oct. 2017.
13.
Kei Yamamoto, S. Fujino, Y. Miki and M. Murakami : Plasmalogen-lysophosphatidylethanolamine mobilized by an epidermal sPLA2 (PLA2G2F) is a novel regulator and biomarker for epidermal-hyperplasic diseases., FASEB Summer Research Conferences on Lysophospholipid and related Mediators., Aug. 2017.
14.
Kei Yamamoto, Y. Miki, Y. Taketomi and M. Murakami : Plasmalogen-lysophosphatidylethanolamine is a novel regulator and biomarker for epidermal-hyperplastic diseases, The 1st International Plasmalogen Symposium, Nov. 2016.
15.
M. Murakami and Kei Yamamoto : A unique plasmalogen pathway driven by secreted phospholipase A2 regulates skin homeostasis and disease, The 1st International Plasmalogen Symposium, Nov. 2016.
16.
Kei Yamamoto, Y. Miki, H. Sato, Y. Taketomi, G. Lambeau, M.H. Gelb and M. Murakami : The two secreted phospholipase A2s PLA2G2F and PLA2G2E play distinct roles in skin homeostasis and diseases., 7th International Conference on Phospholipase A2 and Lipid Mediators, La Jolla, California, USA, May 2016.
17.
Kei Yamamoto, Y. Miki, M. Sato, Y. Taketomi, N. Kambe, K. Kabashima, G. Lambeau, M.H. Gelb and M. Murakami : Plasmalogen-lysophosphatidylethanolamine driven by group IIF sPLA2 underlies epidermal-hyperplastic disorders., The 14th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases., Budapest, Hungary, Jul. 2015.
18.
Y. Taketomi, Y. Endo, Kei Yamamoto, T. Kobayahsi and M. Murakami : Skin abnormalities in group III secreted phospholipase A2-deficient mice., The 14th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases., Budapest, Hungary, Jul. 2015.
19.
R. Murase, Y. Taketomi, H. Sato, Kei Yamamoto, T. Yamamoto and M. Murakami : Group X sPLA2 mobilizes omega-3 polyunsaturated fatty acid metabolites to protect from colitis., The 14th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases., Budapest, Hungary, Jul. 2015.
20.
T. Suzuki-Yamamoto, M. Tanaka, E. Kawai, K. Toda, Y. Serai, T. Mega, Y. Kawakami, Y. Takahashi, Kei Yamamoto, M. Murakami and M. Kimoto : Purification and characterization of bovine lipocalin-type prostaglandin D synthase from cow's milk., The 14th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases., Budapest, Hungary, Jul. 2015.
21.
I. Tsukayama, Y. Takeda, T. Mega, K. Toda, Y. Kawakami, Y. Takahashi, M. Kimoto, Kei Yamamoto, M. Murakami and T. Suzuki-Yamamoto : Preventive effect of discorea japonica on squamous cell carcinoma of the mouse skin involving down-regulation of prostaglandin E2 synthetic pathway., The 14th International Conference on Bioactive Lipids in Inflammation, Cancer and Related Diseases., Budapest, Hungary, Jul. 2015.
22.
I. Tsukayama, Y. Takeda, K. Nakatani, T. Mega, K. Toda, Y. Kawakami, Y. Takahashi, T. Arakawa, Kei Yamamoto, M. Murakami and T. Suzuki-Yamamoto : Dioscorea japonica suppresses COX-2 and mPGES-1 expression and has preventive effects on squamous cell carcinoma., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
23.
N. Ueno, Y. Taketomi, Kei Yamamoto, T. Hirabayashi, H. Nakanishi and M. Murakami : Analysis of two major intracellular PLA2 in mast cells reveals crucial contribution of cPLA2a, not iPLA2b, to lipid mobilization in proximal mast cells and distal fibroblasts., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
24.
A. Irie, Kei Yamamoto and M. Murakami : Phosphatidylethanolamine dynamics in osteoclast fusion., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
25.
R. Murase, Y. Taketomi, H. Sato, Kei Yamamoto, T. Yamamoto and M. Murakami : Group X sPLA2 protects from colitis by mobilizing omega-3 polyunsaturated fatty acid metabolites., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
26.
H. Sato, Y. Taketomi, Kei Yamamoto, S. Hara, K. Miyata, Y. Oike, M. Gelb and M. Murakami : Adipocyte-inducible group V and IIE sPLA2s play distinct roles in metabolic disorders., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
27.
H. Sato, Y. Taketomi, Kei Yamamoto, S. Hara and M. Murakami : Deficiency of group III sPLA2 protects from metabolic disorders., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
28.
Y. Taketomi, N. Ueno, H. Sato, Kei Yamamoto and M. Murakami : Group III sPLA2 facilitates mast cell maturation., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
29.
Y. Endo, Y. Taketomi, Kei Yamamoto, T. Kobayashi and M. Murakami : Skin abnormalities in group III sPLA2-deficient mice., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
30.
T. Anjo, T. Hirabayashi, K. Yokoyama, Kei Yamamoto, A. Naoe, J. Ishikawa, A. Muñoz-Garcia, A. Brash and M. Murakami : Impaired skin barrier function in PNPLA1-deficient mice., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
31.
Yoshimi Miki, Kei Yamamoto and Makoto Murakami : Group IID sPLA2 resolves psoriasis by driving pro-resolving lipid mediators. 6th International conference on phospholipase A2 and lipid mediators., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
32.
Kei Yamamoto, Yoshimi Miki, Mariko Sato and Makoto Murakami : Group IIF sPLA2 promotes skin carcinogenesis., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
33.
Kei Yamamoto, Yoshimi Miki, Yoshitaka Taketomi, Naotomo Kambe, Kenji Kabashima, Gerard Lambeau, Michael Gelb and Makoto Murakami : A unique lipid pathway driven by group IIF sPLA2 undelies epidermal-hyperplasic disorders., 6th International conference on phospholipase A2 and lipid mediators., Tokyo, Feb. 2015.
Kei Yamamoto : The combination technology of gene-engineered mice and lipidomics elucidates new lipid pathwaysDiscovery of new bioactive lipid as a regulator of epidermal hyperplastic diseases., 第33回日本乾癬学会学術大会, Sep. 2018.
41.
Ryosuke Watanabe, Daisuke Tsuji, Hiroki Tanaka, Shintaroh Michael Uno, Yukiya Ohnishi, Kei Yamamoto, 広川 貴次, 沖野 望, 伊東 信 and Kouji Itou : Lysoスフィンゴ糖脂質が神経細胞死を起こす分子メカニズムの解明, 第37回日本糖質学会年会, Aug. 2018.
入江 敦, Kei Yamamoto and 村上 誠 : リン脂質動態に基づく破骨細胞融合機構の解明, 第57回日本脂質生化学会, May 2015.
63.
Kei Yamamoto, 三木 寿美 and 村上 誠 : IIF型分泌性ホスホリパーゼA2により産生されるアルケニル型リゾホスファチジルエタノールアミンは表皮肥厚性疾患のバイオマーカーである, 第57回日本脂質生化学会, May 2015.
64.
武富 芳隆, 遠藤 由妃, Kei Yamamoto, 小林 哲幸 and 村上 誠 : Ⅲ型ホスホリパーゼA2は皮膚バリア恒常性に関わる, 第57回日本脂質生化学会, May 2015.
Et cetera, Workshop:
1.
Kei Yamamoto : Novel bioactive lipids, acetal-type lysoplasmalogen, a secondary product of group IIF phospholipase A2., Wayne state University, Seminar, Nov. 2022.
2.
Kei Yamamoto : The technology of Lipidomics elucidates new lipid pathways: Discovery of new lysophospholipid as a regulator of epidermal hyperplastic diseases., National Chiayi University. Chiayi, Taiwan. Seminar., Mar. 2018.
3.
Kei Yamamoto : The technology of Lipidomics elucidates new lipid pathways: Discovery of new lysophospholipid as a regulator of epidermal hyperplastic diseases., Wayne state University. Detroit, MI, USA. Seminar, Oct. 2017.
New paradigm of lipid metabolism in health sciences (Project/Area Number: 16H02613 )
Assessment of high functionality of Dioscorea japonica and development of dysphagia diet using the yam (Project/Area Number: 15K00792 )
Identification of new skin disease biomarkers by lipid metabolome analyses and establishment of foundation for medical treatment (Project/Area Number: 26461671 )
Exploration of food functionality of Dioscorea japonica targeting lipid mediator (Project/Area Number: 24500948 )
Analyses of lipid network using inflammatory dermatoses model mice (Project/Area Number: 23591665 )
Elucidation of possible functional mechanisms of secretory phospholipase A2 in skin pathophysiology (Project/Area Number: 21791106 )
Analyses of pathophysiological functions of prostaglandin E synthases as a potential target for novel anti-inflammatory drugs (Project/Area Number: 18390033 )